Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients

  • STATUS
    Recruiting
  • End date
    Mar 31, 2024
  • participants needed
    382
  • sponsor
    Tongji Hospital
Updated on 28 January 2021

Summary

Neuraminidase-1 can cause the removal of terminal sialic acid residues from the cell surface or serum sialyloconjugates. The level of Neu5Ac was positively related to the activity of neuraminidase-1. Elevation of Neu5Ac was observed in myocardial ischemia animal model, as well as patients with coronary artery disease. It is interesting to note that Neu5Ac and its regulatory enzyme neuraminidase-1 seem to play a key role in triggering myocardial ischemic injury. Oseltamivir, a structural mimic of sialic acid, was widely used as anti-influenza drug. It suppressed neuraminidase-1 activity in the heart. Targeting neuraminidase-1 may represent a new therapeutic intervention for coronary artery disease. This project seeks to identify whether neuraminidase inhibitor (Oseltamivir) treatment could decrease the myocardial infarct size in STEMI patients and improve clinical outcomes.

Details
Condition Myocardial Infarction, Heart Attack (Myocardial Infarction), Heart Attack (Myocardial Infarction), STEMI, ST Elevation Myocardial Infarction
Treatment Oseltamivir phosphate capsules
Clinical Study IdentifierNCT04684498
SponsorTongji Hospital
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Between the ages of 18 and 75, regardless of gender
STEMI should be diagnosed by two attending physicians or above, including history, clinical symptoms and signs
Participate voluntarily and sign informed consent, and can be followed up for more than one month

Exclusion Criteria

Allergic to oseltamivir
Creatinine clearance rate less than 60%
Severe liver insufficiency
Female patients who have or plan to become pregnant
Life expectancy less than one year
Patients refused to comply with the requirements of this study
According to the discretion of investigator, the patient was unable to complete the study or comply with the requirements of the study (for administrative or other reasons)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note